Happy new year, everyone! Wishing 2025 will be a better year for everyone! What is your top priority goal for 2025? NOTE: if you have something else in mind, feel free to comment Here is my 2025 Financial Goals: For 2024, I have achieved 7% ROI (including P/L from my other MY trading account). Seeing the good result for my portfolio, I am targeting to achieve 10% ROI for my next goal.With such result, I gain confidence for my trading strategy. The ROI result is diluted ...
The U.S. stock market began September with a jolt for investors, as August's non-farm payroll data indicated a faster-than-expected cooling of the labor market, heightening economic slowdown worries and dampening risk appetite. Read Here: Here's the Breakdown for US August Nonfarm Payrolls, in One Chart With the rate cut cycle approaching, savvy investors are seeking new opportunities. Beyond previously noted sectors like healthcare, uti...
NVR's high ROCE and reinvestment at high rates are positive signs for long-term growth. Despite positive trends, the stock is still worth investigating.
Insider selling of NVR stock, especially by Senior VP Daniel Malzahn, is concerning. The absence of insider buying in the past year amplifies this worry. Yet, insiders owning a substantial amount of company shares is a positive, indicating alignment of management's incentives with shareholders.
John Wells PhD Math
:
I think the problem with your portfolio performance is your model for calculating fair value of the stocks. I just looked at MED and based on a dividend discount method, I calculate the fair value to be zero. They are expecting to lose money, and I don’t see any prospect for that changing, which means that it has some assets, but they’re just going to slowly burn through the cash until there’s nothing left. I think you would be better served with VTI or VOO, the Vanguard total market ETF or the Vanguard S&P 500 ETF. With either of those at least you will match the market performance, which would put you substantially ahead of where you are.
CarilonCapital
OP
John Wells PhD Math
:
My valuation of $Medifast (MED.US)$ in this and other vids were done when the company was still profitable and had high FCF. Based on recent financials it’s clear that the company’s price collapse was not justified. I released this video a year ago. Estimating fair value still requires projecting fcf and discounting.
The stock's fair valuation coupled with a negative growth outlook heightens risk. Uncertainty from potential negative returns suggests it might be time to reduce portfolio risk. Buying now may not be advantageous as it's trading around its fair value.
Despite NVR's high ROE and total profit reinvestment driving decent earnings growth, future shrinkage is anticipated by analysts. Without dividends, maintaining efficient profit reinvestment for future growth is crucial.
103746526 : learning the ropes still
w r : Thank you![pray 🙏](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f64f.png)